Product Description
Mechanisms of Action: Tubulin Inhibitor, Mitosis Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Gliosarcoma|Glioblastoma
Phase 2: Glioblastoma|Glioma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma
Phase 1: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Burkitt Lymphoma|Follicular Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Renal Cell Carcinoma|B-Cell Leukemia|Mantle-Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Glioblastoma|Oncology Solid Tumor Unspecified|Lymphoma, B-Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03123952 |
C16-478 | N/A |
No longer available |
Glioblastoma |
None |
2019-07-21 |
Treatments|Trial Status |
|
CTR20170455 |
CTR20170455 | N/A |
Unknown |
Glioblastoma |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT01800695 |
M12-356 | P1 |
Completed |
Glioblastoma |
2017-06-19 |
2024-06-26 |
Primary Endpoints |
|
NCT01786096 |
SGN19A-001 | P1 |
Completed |
Burkitt Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia |
2017-05-30 |
2019-03-19 |
Treatments |
|
NCT01741727 |
M13-379 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2015-11-01 |
2019-03-19 |
Treatments |
|
NCT01786135 |
SGN19A-002 | P1 |
Completed |
Burkitt Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia |
2015-08-01 |
2019-03-19 |
Treatments |
|
NCT01677390 |
SGN75-002 | P1 |
Terminated |
Renal Cell Carcinoma |
2013-12-01 |
2020-10-28 |
Primary Endpoints|Treatments |
|
NCT01015911 |
SGN75-001 | P1 |
Completed |
Lymphoma, Non-Hodgkin|Renal Cell Carcinoma |
2011-11-01 |
2020-10-28 |
Primary Endpoints|Treatments |
|
NCT02590263 |
M13-714 | P2 |
Completed |
Glioma|Glioblastoma |
2020-08-27 |
12% |
2020-09-09 |
Primary Endpoints |
NCT02343406 |
INTELLANCE-2 | P2 |
Completed |
Glioblastoma |
2019-06-24 |
12% |
2020-05-23 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
2014-004438-24 |
2014-004438-24 | P2 |
Completed |
Glioblastoma|Glioma |
2019-06-24 |
12% |
2022-03-13 |
Treatments |
NCT02592876 |
SGN19A-003 | P2 |
Terminated |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma |
2018-04-20 |
67% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT02855359 |
SGN19A-004 | P2 |
Terminated |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma |
2018-01-01 |
64% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT02573324 |
Intellance1 | P3 |
Completed |
Glioblastoma|Gliosarcoma |
2022-04-04 |
74% |
2023-05-12 |
Primary Endpoints|Treatments |
2015-001166-26 |
2015-001166-26 | P3 |
Completed |
Glioblastoma|Gliosarcoma |
2022-04-04 |
74% |
2022-03-13 |
Treatments |
2017-003171-64 |
2017-003171-64 | P3 |
Completed |
Glioblastoma |
2020-03-03 |
22% |
2025-06-29 |
Treatments |
NCT03419403 |
UNITE Study | P3 |
Terminated |
Glioblastoma |
2019-09-05 |
22% |
2021-04-15 |
Primary Endpoints|Treatments|Trial Status |